| Date | Title | | | 05/20/13 | ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index| SAN DIEGO--(BUSINESS WIRE)--May. 20, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, announced
that it has been selected for addition to the NASDAQ Biotechnology Index
(NASDAQ: ^NBI) effective prior to today’s market open.
The NASDAQ Biotechnology Index is designed to track the performance ... |
|  | | 05/20/13 | ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock| SAN DIEGO--(BUSINESS WIRE)--May. 20, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the
completion of an underwritten public offering of 9,200,000 shares of its
common stock, including 1,200,000 shares sold pursuant to the full
exercise of an option to purchase additional shares previously granted
to the underwriters. All of the shares were offered by ACADIA at a price
to the public of $12.50 per share. The gross proceeds from this off... |
| | | 05/15/13 | ACADIA Pharmaceuticals Prices Public Offering of Common Stock| SAN DIEGO--(BUSINESS WIRE)--May. 15, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing
of an underwritten public offering of 8,000,000 shares of its common
stock, offered at a price to the public of $12.50 per share. The gross
proceeds from this offering to ACADIA are expected to be $100 million,
before deducting underwriting discounts and commissions and other
estimated offering expenses payable by ACADIA. ACADIA has granted ... |
| | | 05/14/13 | ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock| SAN DIEGO--(BUSINESS WIRE)--May. 14, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it
intends to offer and sell, subject to market and other conditions,
shares of its common stock in an underwritten public offering. There can
be no assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Jefferies LLC and Cowen and Company, LLC are acting as the joint
book-ru... |
| | | 05/07/13 | ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May. 7, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced its unaudited financial results for the first quarter ended
March 31, 2013.
ACADIA reported a net loss of $6.1 million, or $0.08 per common share,
for the first quarter of 2013 compared... |
| | | 04/30/13 | ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013| ACADIA to Host Conference Call and Webcast on Tuesday, May 7, 2013,
at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Apr. 30, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will report its unaudited financial results for the
first quarter ended March 31, 201... |
| | | 04/25/13 | ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013| SAN DIEGO--(BUSINESS WIRE)--Apr. 25, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the 12th Annual Needham
Healthcare Conference on Tuesday, April 30, 2013, at 8:00 a.m. Eastern
Time at The Westin New York Grand Central Hotel in New York City.
... |
| | | 04/11/13 | ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA| Single Pivotal Phase III -020 Study and Other Supportive Data
Sufficient for Future NDA Filing for the Treatment of Parkinson’s
Disease Psychosis
Conference Call and Webcast to Be Held Today, April 11, 2013, at 8:00
am Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Apr. 11, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurolo... |
| | | 03/20/13 | ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting| SAN DIEGO--(BUSINESS WIRE)--Mar. 20, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, announced
that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou
Ruvo Center for Brain Health, presented detailed results today from
ACADIA’s pivotal Phase III -020 Study with pimavanserin in pati... |
| | | 03/13/13 | ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013| SAN DIEGO--(BUSINESS WIRE)--Mar. 13, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 25th Annual ROTH Conference on Tuesday, March 19, 2013, at 10:00 a.m. Pacific Time at The Ritz-Carlton in Laguna Niguel.
A live webcast of ACADIA's presentation will be accessible on the company's website, www.... |
| | | 03/12/13 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012| SAN DIEGO--(BUSINESS WIRE)--Mar. 12, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced its financial results for the fourth quarter and year ended
December 31, 2012.
ACADIA reported a net loss of $6.8 million, or $0.11 per common share,
for the fourth quarter of 201... |
| | | 03/05/13 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013|
ACADIA to Host Conference Call and Webcast on Tuesday, March 12,
2013, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Mar. 5, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will report its financial results for the fourth
quarter and year e... |
| | | 02/25/13 | ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013| SAN DIEGO--(BUSINESS WIRE)--Feb. 25, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the Cowen and Company 33rd
Annual Health Care Conference on Monday, March 4, 2013, at 1:30 p.m.
Eastern Time at the Boston Marriott Copley Place.
A live we... |
| | | 02/05/13 | ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013| SAN DIEGO--(BUSINESS WIRE)--Feb. 5, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, announced
that it will present at the 15th Annual BIO CEO & Investor
Conference on Tuesday, February 12, 2013, at 10:00 a.m. Eastern Time at
The Waldorf=Astoria Hotel in New York City.
A live ... |
| | | 01/22/13 | ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors| SAN DIEGO--(BUSINESS WIRE)--Jan. 22, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced the election of Stephen R. Biggar, M.D., Ph.D., to its board
of directors. Dr. Biggar will fill a vacancy on ACADIA’s board and serve
as a Class II director. The terms of the Class II directors ... |
| |
|
